N-异丙基-3-溴苯磺酰胺 | 871269-08-8

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-异丙基-3-溴苯磺酰胺
• 中文别名: 3-溴-n-异丙基苯磺胺
• 英文名称: 3-bromo-N-(1-methylethyl)benzenesulfonamide
• 英文别名: 3-bromo-N-isopropyl-benzenesulfonamide；3-Bromo-N-isopropylbenzenesulfonamide；3-bromo-N-propan-2-ylbenzenesulfonamide
• CAS: 871269-08-8
• 化学式: C₉H₁₂BrNO₂S
• mdl: MFCD07363820
• 分子量: 278.17
• InChiKey: YEZCGZSKQXNVDX-UHFFFAOYSA-N

物化性质

• 熔点：
  52-56
• 沸点：
  359.1±44.0 °C(Predicted)
• 密度：
  1.467±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Isopropyl 3-bromobenzenesulfonamide
Product Name:
Synonyms: N-Isopropyl 3-bromophenylsulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Isopropyl 3-bromobenzenesulfonamide
Ingredient name:
CAS number: 871269-08-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H12BrNO2S
Molecular weight: 278.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-异丙基-3-溴苯磺酰胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 异丙醇 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  新型 2,4-二苯氨基嘧啶衍生物作为有效双重 janus 激酶 2 和组蛋白脱乙酰酶抑制剂的合成和生物学评价

  摘要：

  在单个分子中双重或多重靶向抑制致癌靶点可能是药物组合的替代方法。先前的研究表明，组蛋白去乙酰化酶 (HDAC) 抑制剂与 janus 激酶 (JAK) 抑制剂联合使用可在癌症治疗中发挥协同抗增殖作用。在此，我们提出了一系列新型 2,4-二苯氨基嘧啶衍生物，可同时抑制 JAK2 和 HDAC1。其中，7l被发现是最有效的化合物，并分别显示出对 HDAC1 (IC 50  = 1.9 nM) 和 JAK2 (IC 50  = 0.5 nM) 的平衡抑制活性。7升还对测试的癌细胞系（A549、HepG-2、MDA-MB-231 和 Jurkat）显示出良好的抗增殖活性。此外，流式细胞术分析表明，7l以剂量依赖性方式诱导细胞凋亡和细胞周期停滞，对7l机制的深入了解表明，它可以降低 STAT-3 的磷酸化并促进组蛋白乙酰化。总之，这些结果共同表明7l将是一个有前途的主要候选物，值得进一步研究和开发。

  DOI：

  10.1016/j.molstruc.2021.132200
• 作为产物：
  描述：

  3-溴苯磺酰氯 、 异丙胺 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 N-异丙基-3-溴苯磺酰胺
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Long-acting β₂ Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups

  摘要：

  A series of saligenin alkoxyalkylphenylsulfonamide beta(2) adrenoceptor agonists were prepared by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection. The meta-substituted primary sulfonamide was more potent than the para and the ortho-analogues. Primary sulfonamides were more potent than the secondary and tertiary analogues. The onset and duration of action in vitro of selected compounds was assessed on isolated superfused guinea pig trachea. Sulfonamide 29b had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus. Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation. Crystalline salts of 29b were identified that had suitable properties for inhaled administration. A proposed binding mode for 29b to the beta(2)-receptor is presented.

  DOI：

  10.1021/jm801016j

文献信息

• [EN] BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER<br/>[FR] DÉRIVÉS BENZOXAZEPIN-4-(5H)-YLE ET LEUR UTILISATION POUR TRAITER LE CANCER
  申请人：EXELIXIS INC

  公开号：WO2010118208A1

  公开（公告）日：2010-10-14

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  这项发明涉及公式I的化合物及其药用可接受的盐或溶剂合物，以及制备和使用这些化合物的方法。
• Bi-aryl meta-pyrimidine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20070259904A1

  公开（公告）日：2007-11-08

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供了具有一般结构（A）的联苯基间吡嘧啶化合物。本发明的吡嘧啶化合物能够抑制激酶，如Jak激酶家族成员以及其他特定的受体和非受体激酶。
• Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases
  申请人：Noronha Glenn

  公开号：US20090275582A1

  公开（公告）日：2009-11-05

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供具有一般结构（A）的双芳基间位嘧啶化合物。本发明的嘧啶化合物能够抑制激酶，如Jak激酶家族的成员，以及各种其他特定的受体和非受体激酶。
• Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
  申请人：de Hostos Eugenio L.

  公开号：US20110288093A1

  公开（公告）日：2011-11-24

  The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of chloride channel by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof

  本发明涉及一种治疗动物疾病的方法，该疾病对通过给需要该药物的哺乳动物施用本文定义的化合物（包括表1-3中列出的化合物或公式I-III所包含的化合物）或其组合物阻断氯离子通道产生反应的有效量敏感。
• COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES
  申请人：Penrose Stephen David

  公开号：US20120129858A1

  公开（公告）日：2012-05-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula I-III) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物疾病的组合物和方法，该疾病对通过给予需要的哺乳动物有效量的本文中定义的化合物（包括表1-3中列出的化合物或公式I-III所包含的化合物）或其组合物抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊肾病的方法。